REVB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics...

Stats
Šios dienos apimtis	64 242.00
Vidutinė apimtis	232 822
Rinkos kapitalizacija	3.84M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-5.39 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.43
ATR14	$0.0480 (2.04%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Tidmarsh George F	Sell	27 771	Common Stock
2023-10-16	Tidmarsh George F	Sell	1 845	Common Stock
2023-10-16	Tidmarsh George F	Sell	10 957	Common Stock
2023-09-27	Chawla Lakhmir S	Buy	0
2023-09-28	Tidmarsh George F	Sell	1 429	Common Stock

INSIDER POWER
-12.72
Last 48 transactions
Buy: 316 523 \| Sell: 2 020 596

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: -0.66 (moderate negative)

Signal:(48.807) Neutral

Revelation Biosciences, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
CNSL	0.915
EYE	0.915
AHCO	0.912
CCSI	0.905
DISH	0.879
COLB	0.878
ALHC	0.875
GBNH	0.872
CPTN	0.868
CSSE	0.864

10 Labiausiai neigiamai susiję koreliacijos
KTCC	-0.913
JBSS	-0.895
RKDA	-0.883
HCDI	-0.882
HTBI	-0.874
WINT	-0.874
MBIN	-0.867
HUBG	-0.867
PESI	-0.861
WIRE	-0.859

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Revelation Biosciences, Koreliacija - Valiuta/Žaliavos

-0.48
( neutral )

-0.20
( neutral )

-0.07
( neutral )

-0.73
( moderate negative )

0.87
( strong )

0.77
( moderate )

Revelation Biosciences, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-25 049.00 (0.00 %)
EPS:	$-0.530

FY	2023
Pajamos:	$0
Bruto pelnas:	$-25 049.00 (0.00 %)
EPS:	$-0.530

FY	2022
Pajamos:	$0
Bruto pelnas:	$-40 008.00 (0.00 %)
EPS:	$-600.77

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.310

Financial Reports:

No articles found.

Revelation Biosciences,

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.